Cell and molecular mechanisms of keratinocyte function stimulated by insulin during wound healing
© Liu et al; licensee BioMed Central Ltd. 2009
Received: 05 September 2008
Accepted: 12 January 2009
Published: 12 January 2009
Regenerative wound repair is a goal of modern medicine. This is important not only for the local repair but also for its beneficial effect to systemic physiological processes. When wounds become chronic, individuals are susceptible to generalized inflammatory cascades that can affect many organs and even lead to death. Skin is the most commonly injured tissue, and its proper repair is important for reestablishment of its barrier function.
We show here that insulin, when topically applied to skin excision wounds, accelerates re-epithelialization and stimulates "maturation" of the healing tissue. These effects are dependent on the insulin receptor but independent of EGF/EGF-R; PI3K-Akt-Rac1 signaling pathways are critically involved, and healing is α3 and LN332-dependent.
Insulin has great potential for the treatments of chronic wounds in which re-epthelialization is impaired. Understanding of the pathways induced by insulin is important for the development of analog molecules that function strictly in healing. Because of its long history of safe use in humans for decades, this protein may prove to be a powerful therapy without major adverse effects.
Wound healing is a complex process that involves sequential phases that overlap in time and space, interact, and affect each other dynamically both at the gene and protein levels. In addition, crosstalk between cells and the surrounding microenvironment contributes to the processes of clot formation, inflammation, granulation tissue development, and remodeling. Many different lines of experimental evidence have shown that the basic cellular and molecular mechanisms that result in these events involve cell adhesion/de-adhesion, migration, proliferation, differentiation, and apoptosis. One important process initiated during the early stages of healing is re-epithelialization; it involves the proliferation, migration, and differentiation of keratinocytes from the wound margins [1, 2]. Appropriate re-epithelialization requires not only the development of a continuous epidermal layer but also full epidermal differentiation and the formation of junctions between the epidermis and dermis. Because the epidermis provides a barrier against infection and maintains homeostasis, improving re-epithelialization, particularly in impaired healing situations, has attracted a great deal of attention. One molecule with the potential to enhance these processes is insulin, a hormone known to maintain the growth and development of different cell types. It can affect the proliferation, migration , and ECM secretion by keratinocytes, endothelial cells, and fibroblasts .
The use of insulin for non-diabetic purposes was popular in the early part of the 20th century [5, 6], was "forgotten" during the 40's and 50's, and it became again reinvigorated during the latter half of the century. For example, daily injections of insulin were used to improve bone healing in rats [7, 8], incision wounds of the skin [9, 10], healing in the distal limb of horses , and in cutaneous ulcerations in diabetic and non-diabetic mice . Insulin was also used in the 60's to treat diabetic wounds in humans [13, 14], and more recently, insulin spray has been successfully used to treat patients with diabetic ulcers. Furthermore, this hormone has been used to treat burns in humans , rats , and rabbits  with good success. In addition to the studies in vivo, experiments with cultured cells have shown that insulin increases the rate of growth of fibroblasts, cells that are critically involved in the development of the granulation tissue , suggesting that insulin can function as a growth hormone . Nevertheless, despite the strong evidence that insulin stimulates healing and thereby decreases the time of wound closure, the underlying mechanisms of insulin-induced improved healing are far from understood.
Here we show that local application of insulin to excision wounds stimulates keratinocyte migration and differentiation, and that this is dependent on activation of the PI3K-Akt pathway, followed by activation of Rac1, and that the integrin α3 and the ECM molecule laminin 332 (LN332), are critical. We also show that insulin stimulates a regenerative process in the wound tissue. Therefore, insulin may prove to be useful in the treatment of chronic wounds, dental/gum healing problems, and burns. These are important findings because issues of impaired healing and of lack of tissue regeneration have implications for numerous health- and financially-related problems in this country and elsewhere. The understanding of key elements of the signaling pathways induced by insulin during stimulation of healing can lead to the development of analogs that will function strictly in the healing process.
Topical application of insulin accelerates and improves the quality of healing
Insulin stimulates keratinocyte migration in a time- and dose-dependent manner
Insulin stimulates keratinocyte migration in an insulin receptor-dependent manner but in an EGF-independent manner
Our previous studies showed that insulin stimulates EGF expression in wound marginal keratinocytes of deep partial thickness scald wounds in rats . In order to exclude the potential autocrine effects of EGF secretion on insulin-induced keratinocyte migration, we treated the keratinocytes with AG1478, a selective inhibitor of EGF-R kinase, prior to treatment with insulin and measured migration distances at 24 and 48 h. This EGF-R inhibitor did not inhibit the effects of insulin on keratinocyte migration (Fig. 3C), suggesting that this process does not require EGF or its receptor.
PI-3K and Akt mediate insulin-induced keratinocyte migration
PI3K is often involved in AKT phosphorylation. Therefore, to determine whether insulin stimulation of keratinocyte migration is dependent on PI3K activity, we performed the migration assays in the presence of LY294002, an inhibitor of PI3K. This treatment completely blocked keratinocyte migration stimulated by insulin (Fig. 4F), showing the importance of PI3K in this process. The dose of LY294002 we used does not inhibit S6 kinase, which is the effector of mTOR, nor does it affect MAP kinase, PKC, or PI4K .
Insulin stimulates translocation of Rac1, but not RhoA, to the plasma membrane; this process requires PI3K-Akt activation and is involved in insulin-induced keratinocyte migration and wound healing
Insulin stimulates integrin a3 and LN332 production, which contributes to insulin-induced keratinocyte migration and wound healing
Using similar methodology, LN332 was also found to be elevated after insulin treatment, particularly at the migrating edge, with deposition of LN332 along the cell membrane in some cells (Fig. 6D, E and inserts). Immunoblot analysis showed an increase in the LN332 protein after insulin treatment (Fig. 6F). To determine whether these observations translate into changes in the migratory behavior of keratinocytes, we observed the effect of function-inhibiting Abs to integrin α3 and LN332 on insulin-induced keratinocyte migration (Fig. 6G). Cell migration was inhibited when integrin α3 or LN332 were blocked with these Abs, while basal migration remained virtually unaffected. The effects of these blocking antibodies were more obvious after 48 h of insulin treatment; at this time point, functional blocking of α3 and LN332 affected both basal and insulin-induced keratinocyte migration. Moreover, additional inhibition was observed when insulin treatment was accompanied by treatment with both integrin α3 and LN332 function-inhibiting Abs (Fig. 6G).
Previous work has shown that insulin improves wound healing, but the mechanisms of its action on healing have not been delineated. We used a variety of cell and molecular approaches to determine the effects of insulin on cutaneous wounds and have shown that insulin: (1) stimulates keratinocyte migration in a dose- and time-dependent manner; (2) acts in an insulin-receptor-dependent but EGF/EGF-R-independent manner; (3) stimulates keratinocyte migration through the PI3K-Akt-Rac1 pathway; (4) stimulates keratinocytes to produce integrin α3 and LN332, and cell migration in vitro and in vivo is dependent on these molecules. The ability of this hormone to stimulate a variety of cell functions important for wound healing in an insulin-receptor-dependent manner creates the ability to target processes that are dependent only on insulin. Conversely, the ability to stimulate both the insulin and IGF-1 receptors may broaden the applicability of insulin in different wound conditions, particularly when one receptor may be missing or dysfunctional (e.g. type II diabetes).
Understanding the processes by which insulin accelerates wound closure is important because it will provide insight into potential manipulation of the healing process using this hormone as well as the signaling molecules it activates. The results presented here show that stimulation of keratinocyte migration by insulin involves the PI3K-Akt pathway, and identifies Rac1, a small GTPase, as a molecule activated downstream of PI3K-Akt. Support for these conclusions includes the fact that these molecules are activated upon insulin stimulation, and inhibition of each molecule with specific inhibitors or dominant negative proteins prevents insulin-induced keratinocyte migration.
Rac1 is known to regulate actin assembly  and to stimulate formation of lamellipodia , thereby promoting cell movement in response to external signals from cytokines, growth factors and/or the ECM. Our results support insulin-induced Rac1 activation in keratinocytes, as shown by Rac1 translocation from the cytosol to the cell membrane, the formation of membrane ruffles upon insulin stimulation, and the increased levels of active Rac1 identified by the pull down assay. Moreover, we show that Rac1 activation is dependent on the PI3K-Akt signaling pathway in keratinocyte migration. Two recent papers showed a strong activation of the PI3K pathway in the wound margin keratinocytes [28, 29]. Furthermore, epidermal growth factor (EGF) or heregulin (HRG) have been found to stimulate keratinocyte migration through PI3K/Akt signaling . These results, coupled with our findings presented here, show that insulin can replace some well known growth factors in wound healing.
The effects of insulin on keratinocyte migration described above, led us to hypothesize that insulin-accelerated wound healing involves increased expression of the integrin α3β1 in keratinocytes as well as an increase in the levels of LN332. The latter protein is a matrix molecule secreted by migrating keratinocytes at the leading edge , where it mediates keratinocyte polarity and persistent migration [32, 33]. After wounding, quiescent epidermal keratinocytes are activated and express the integrins α6β4 and α3β1, which mediate their migration on LN332 and facilitate the development of the BM . Our results show that insulin stimulates keratinocyte integrin α3 expression and LN332 deposition, and that inhibition of these proteins in vitro or in vivo inhibits insulin-induced keratinocyte migration and wound healing, strongly suggesting an important role for these molecules in insulin stimulation of healing. This is a particularly important finding, as the relationship between LN332 and migration has been controversial. Indeed, previous studies have implicated LN332 in promoting and inhibiting cell migration [34–36]; our results support a role for LN332 in promoting keratinocyte migration.
In addition to its effects on keratinocyte migration during wound healing, insulin also promotes attachment of the epidermis to the dermis, the appearance of a well-organized epidermis, increased numbers of skin appendages, and more dermal papilla and epidermal reticular ridges. We also found that inhibiting integrin α3 and LN332 resulted in lack of full epidermal differentiation (as shown by disorganization of the epidermis) and decreased formation of dermal papilla and epidermal reticular ridges.
Our results suggest that the direct application of insulin to chronic wounds may improve wound healing by compensating for a deficiency of insulin and/or IGF-1 in the injured area. Previous studies have shown that the IGF-1 level is decreased in both streptozotocin (STZ)-induced diabetic and normal rat incision wounds , and we have also detected a decrease in insulin levels in rat scald wounds (unpublished data). This insulin and IGF-1 deficiency in the wound, along with our data showing that insulin can function through stimulation of both insulin and IGF-1 receptors, suggests that direct application of insulin to the wound area may improve healing through activation of both receptors. Indeed, it has been shown that topical application of insulin accelerates healing of infected cutaneous ulcerations in diabetic mice , showing that insulin is promising for treatment of these types of wounds. However, it has also been shown that leptin-deficient obese/obese (ob/ob) diabetic mice have dysfunctional signaling during wound healing , suggesting that in these mice mediating the effect of insulin on wounds might be different from those in normal wounds or wounds in diabetic people.
When compared with other growth factors used to promote wound repair, insulin treatment is likely to be much less expensive, more readily available, and has already been approved by the FDA for human use. Moreover, a significant numbers of reports have described that treatment with growth factors, including most of the growth factors that have been used clinically, or increased expression of growth factor receptors, lead to carcinogenesis [39–41]. In contrast, insulin is safe, as shown by its use for nearly a hundred years, hence it is likely safer than growth factor alternatives. When choosing a concentration of insulin for possible wound therapy, it is important to remember that, although the highest concentrations of insulin resulted in the greatest keratinocyte migration, such doses may alter blood glucose levels in vivo.
In conclusion, we have shown that insulin interacts with its receptor and affects multiple aspects of keratinocyte behavior, including stimulation of cell motility, increased expression of the cell surface adhesion molecule integrin α3 and enhanced secretion of the ECM molecule LN332. Furthermore, these effects extend to the dermis where we observe a higher degree of tissue restoration than seen in the control. These results strongly suggest that insulin improves wound healing through an integrated effect not only on re-epithelialization but also on the underlying granulation tissue. Therefore, insulin treatment may prove to be a powerful therapy for the treatment of impaired wounds, especially given the fact that insulin has been used in humans for a century without serious adverse consequences.
The human keratinocyte cell line HaCaT was a gift from DKFZ (German cancer research center). DMEM was purchased from Mediatech and FBS from Atlanta Biologicals. Anti-RhoA (sc-179) Abs was purchased from Santa Cruz Biotechnology. Anti-phospho-Akt Ser (473), anti-insulin receptor (29B4) Abs and the PI-3K inhibitors, LY294002 came from Cell Signaling. The TRITC-anti-mouse Rac1 Ab was purchased from Becton Dickinson and Company. And the anti-human LN332 (P3H9-2) and anti-human integrin α3 (P1B5) Abs were purchased from Chemicon. The anti-mouse cytokeratin 10 Ab and rabbit polyclonal to type collagen IV Ab were from Abcam. Anti-GAPDH Ab was obtained from RDI Research Diagnostics. Recombinant human insulin and mitomycin C were purchased from Sigma. Humulin Ultralene human insulin (rDNA origin) extended zinc suspension was purchased from Eli Lilly and Company. EGF-R inhibitor AG1478 and IGF-1 receptor tyrosine kinase inhibitor, Picropodophyllin were purchased from Calbiochem. FITC-conjugated goat anti-mouse immunoglobulin came from DAKO, and anti-mouse Texas Red Ab from Amersham.
In vivo wound model
C57BL/6J mice were purchased from The Jackson Laboratory (USA), and housed at the University of California, Riverside (UCR) vivarium. All experimental protocols were approved by the UCR Institutional Animal Care and Use Committee. Experiments were performed using 8–12 wk old mice. Mice were anesthetized with a single intraperitoneal injection of ketamine (80 mg/kg body weight)/xylazine (16 mg/kg body weight). Full-thickness 7 mm punch wounds (excision of the skin and the underlying panniculus carnosus) were made on the back of the mice. The wounds were then treated as indicated for the various experiments and covered with a transparent dressing (Bioclusive, Johnson & Johnson Medical Limited, USA) until day 3 after wounding. After this time, the dressings were removed, and the wounds were exposed. Healing was monitored by taking photographs at the indicated time points. In addition, the wound area was drawn on a transparent plastic film for further comparisons of wound area at each time point. For graphing purposes, wound closure was expressed as percentage of wound area (area of wound measured at any one day post wounding divided by the initial wound area).
At day 3 after wounding, as well as the day that complete healing occurred, animals were anesthetized, and skin samples consisting of the wounded area plus 5 mm of the surrounding unwounded and/or healed skin area were collected. Tissues were fixed in 4% pareformaldehyde for 2 h and incubated in 0.1 M glycine/PBS for 1 h followed by 15% and 30% sucrose before embedding in OCT (Tissue-Tek, Sakura Finetek. USA, Inc), freezing in a slush of ethanol/dry ice, and stored in -80 C. After sample collection, the mice were euthanized using CO2. The extent of migration of the keratinocyte was measured in sections stained with Hematoxylin and Eosin. The length of migration tongue was determined by the distance from the margin of the wound to the tip of the migrating keratinocytes.
The human keratinocyte cell line HaCaT was cultured in 5% CO2 at 37°C in DMEM supplemented with 10% FBS, 10 units/ml penicillin, and 10 μg/ml streptomycin sulfate (GIBCO, Invitrogen Corporation).
Cells were treated as indicated, and then washed with ice-cold 1 × PBS, and lysed on ice with lysis buffer containing 0.5% Triton X100, 0.5% Nonidet P-40, 10 mM Tris, pH 7.5, 2.5 mM KCl, 150 mM NaCl, 30 mM b-glycerophosphate, 50 mM NaF, 1 mM Na3VO4, 0.1% SDS and additional protease and phosphatase inhibitor cocktails (Sigma). Protein concentrations were measured using the DC protein assay kit (Bio-Rad). Equal amounts of protein in the cell extracts were mixed with sample buffer, boiled, and analyzed using 10% acrylamide SDS-PAGE. Immunoblotting was performed with the indicated primary Abs and the appropriate HRP-conjugated secondary Abs, followed by incubation with West Dura extended duration substrate (Pierce Biotechnology). Blots were then re-probed for house keeping proteins to show equal loading. For LN332 and integrin α3, protein extracts were prepared as indicated above, but were mixed with non-reducing sample buffer, and, for LN332 detection, samples were boiled. The extracts were then analyzed using 7.5% acrylamide SDS-PAGE, followed by immunoblotting as described above.
In vitro Migration Assays
We used two types of assays: (i) The cloning ring assay in which 2.0 × 104 HaCaT cells were plated in a cloning ring 6 mm diameter set within a 35-mm cell culture dish. Four hours after seeding, the cylinder was removed, the cell edges were marked, and migration was measured at the indicated times by measuring the distance from the initial cell edge to the edge of the migrating cells; (ii) For the scratch assay the HaCaT cells were plated in cell culture dishes and after reaching confluence, scratch wounds were made as previously described . Briefly, we used the small end of a 1 ml pipet tip to scratch the cells on a 35 mm plate, and then marked the edges of the scratches. Cell migration was measured at the indicated times by measuring the distance from the initial cell edge to the edge of the migrating cells. The scratch assay was used when we performed transfection experiments to avoid trypsinization and re-plating into the cloning ring.
Transient Adenoviral Transfection
Recombinant adenovirus containing the constitutively active mutant of Akt (Akt-CA), the dominant-negative mutant of Akt (Akt-DN), and the parental adenoviral vector (referred to as null) were gifts from John Shyy (UCR, Biomedical Sciences Division). Cells were infected with various recombinant adenoviruses at 50 moi; media was changed after 5 h of incubation with adenovirus. After 48 h of infection, cells were subjected to further treatment, as indicated in the Results section. Plasmids expressing the constitutively active form of Rac1 (V12, Rac1-CA), the dominant-negative mutant Rac1 (N17, Rac1-DN) and the wild type Rac1 (Rac1-WT; gifts from Dr. Miguel Del Pozo, Centro National de Investigaciones Cardiovasculares, Madrid, Spain) were transfected using Lipofectin (Invitrogen, USA) according to the manufacturer's protocol. Briefly, one day before transfection, the cells were plated in growth media without antibiotics. Transfections were performed at 40–60% cell confluence. 2 μg of DNA in 100 μl of DMEM without serum, were mixed gently with 5 μl Lipofectin in 100 μl of MDEM without serum. This mixture was incubated for 15 min at room temperature and then added to the cells which were then incubated at 37°C and 5% CO2 for 16 h. At this time the medium was replaced with medium containing serum and analyzed at the appropriate times.
Cells were cultured in chamber slides (Nunc), and fixed in 4% paraformaldehyde for 20 min, rinsed with PBS, incubated in PBS containing 0.1 M glycine for 20 min, and blocked with 3% BSA, 0.1%Triton X-100 in PBS for 30 min. Primary Abs in 1% BSA/PBS were applied to the sample for 2 h at room temperature, washed, and incubated with 1:50 dilution of FITC or Texas red-conjugated secondary Abs for 1 h at room temperature. After washing, the cells were mounted in Vectashield containing DAPI (Vector Laboratories, Inc. Berlingame, CA). Immunofluorescence was visualized and imaged using a Leica SP2 laser scanning confocal microscope. For frozen tissues, 8-μm cryosections were washed in 1 × PBS to remove the OCT, fixed in 2% paraformaldehyde for 10 min, incubated in 0.1 M glycine in 1 × PBS, followed by the primary and secondary Abs using the same procedure as indicated above.
Data are shown as mean × SD. Data analysis was performed using the unpaired Student's t-test on raw data using GraphPad Instat software (GraphPad Software Inc.). Statistical comparison between more than two groups was performed by One-way ANOVA.
We thank Professor John Shyy for the adenoviral vector mutants for Akt, Dr. Miguel Del Pozo for the Rac1 wild type and mutant plasmids, and Hongwei Yuan and Chongze Ma for helpful discussions.
- Schilling JA: Wound healing. Surgical Clinics of North America. 1976, 56: 859-874.PubMedGoogle Scholar
- Coulombe PA: Wound epithelialization: accelerating the pace of discovery. J Invest Dermatol. 2003, 121: 219-30. 10.1046/j.1523-1747.2003.12387.x.View ArticlePubMedGoogle Scholar
- Benoliel AM, Kahn-Perles B, Imbert J, Verrando P: Insulin stimulates haptotactic migration of human epidermal keratinocytes through activation of NF-kappa B transcription factor. J Cell Sci. 1997, 110: 2089-97.PubMedGoogle Scholar
- Madibally SV, Solomon V, Mitchell RN, Water Van De L, Yarmush ML, Toner M: Influence of insulin therapy on burn wound healing in rats. J Surg Res. 2003, 109: 92-100. 10.1016/S0022-4804(02)00036-7.View ArticlePubMedGoogle Scholar
- King L, Kennaway EL, Piney A: A note on the action of insulin in normal persons. J Physiol. 1928, 66: 400-2.PubMed CentralView ArticlePubMedGoogle Scholar
- Joseph B: Insulin in the treatment of non-diabetic bed sores. Ann Surg. 1930, 92: 318-9. 10.1097/00000658-193008000-00017.PubMed CentralView ArticlePubMedGoogle Scholar
- Gregory WB: Effect of insulin on the healing of bone wounds in albino rats. J Dent Res. 1965, 44: 487-92.View ArticlePubMedGoogle Scholar
- Stunkle G, Wray JB: The effect of exogenous insulin on fracture healing in the intact rat. Clin orthop relat res. 1965, 40: 30-4. 10.1097/00003086-196500400-00006.View ArticlePubMedGoogle Scholar
- Rosenthal SP, brooklyn : Acceleration of primary wound healing by insulin. Arch Surg. 1968, 96: 53-5.View ArticlePubMedGoogle Scholar
- Grewal RS, Gupta SC, Singhal GM, Gupta SN: Wound healing in relation to insulin. Int Surg. 1972, 57: 229-32.PubMedGoogle Scholar
- Edmonds T: Evaluation of the effects of topical insulin on wound healing in the distal limb of the horse. Vet Med Small Anim Clin. 1976, 71: 451-7.PubMedGoogle Scholar
- Hanam SR, Singleton CE, Rudek W: The effect of topical insulin on infected cutaneous ulcerations in diabetic and nondiabetic mice. J Foot Surg. 1983, 22: 298-301.PubMedGoogle Scholar
- Paul TN: Treatment by local application of insulin of an infected wound in a diabetic. Lancet. 1966, 2: 574-6. 10.1016/S0140-6736(66)93041-8.View ArticlePubMedGoogle Scholar
- Lopez JE, Mena B: Local insulin for diabetic gangrene. Lancet. 1968, 1: 1199-10.1016/S0140-6736(68)91898-9.View ArticlePubMedGoogle Scholar
- Pierre EJ, Barrow RE, Hawkins HK, Nguyen TT, Sakurai Y, Desai M, Wolfe RR, Herndon DN: Effects of insulin on wound healing. J Trauma. 1998, 44: 342-5. 10.1097/00005373-199802000-00019.View ArticlePubMedGoogle Scholar
- Liu Y, Zhang X, Zhang Z, Fang PY, Xu WS: Effects of topical application of insulin on the wound healing in scalded rats. Zhonghua Shao Shang Za Zhi. 2004, 20: 98-101.PubMedGoogle Scholar
- Zhang XJ, Wu X, Wolf SE, Hawkins HK, Chinkes DL, Wolfe RR: Local insulin-zinc injection accelerates skin donor site wound healing. J Surg Res. 2007, 142: 90-6. 10.1016/j.jss.2006.10.034.View ArticlePubMedGoogle Scholar
- Straus DS: Growth-stimulatory actions of insulin in vitro and in vivo. Endocr Rev. 1984, 5: 356-69.View ArticlePubMedGoogle Scholar
- Lawrence RT, Salter JM, Best CH: The effect of insulin on nitrogen retention in the hypophysectomized rat. Br Med J. 1954, 2: 437-9.PubMed CentralView ArticlePubMedGoogle Scholar
- Aaronson SA, Rubin JS, Finch PW, Wong J, Marchese C, Falco J, Taylor WG, Kraus MH: Growth factor-regulated pathways in epithelial cell proliferation. Am Rev Respir Dis. 1990, 142: S7-10.View ArticlePubMedGoogle Scholar
- Garza-Garcia A, Patel DS, Gems D, Driscoll PC: RILM: a web-based resource to aid comparative and functional analysis of the insulin and IGF-1 receptor family. Hum Mutat. 2007, 28: 660-8. 10.1002/humu.20491.PubMed CentralView ArticlePubMedGoogle Scholar
- Feng J, Park J, Cron P, Hess D, Hemmings BA: Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase. J Biol Chem. 2004, 279: 41189-96. 10.1074/jbc.M406731200.View ArticlePubMedGoogle Scholar
- Kumar N, Afeyan R, Sheppard S, Harms B, Lauffenburger DA: Quantitative analysis of Akt phosphorylation and activity in response to EGF and insulin treatment. Biochem Biophys Res Commun. 2007, 354: 14-20. 10.1016/j.bbrc.2006.12.188.PubMed CentralView ArticlePubMedGoogle Scholar
- Vlahos CJ, Matter WF, Hui KY, Brown RF: A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem. 1994, 269: 5241-8.PubMedGoogle Scholar
- Leigh IM, Purkis PE, Whitehead P, Lane EB: Monospecific monoclonal antibodies to keratin 1 carboxy terminal (synthetic peptide) and to keratin 10 as markers of epidermal differentiation. Br J Dermatol. 1993, 129: 110-9. 10.1111/j.1365-2133.1993.tb03511.x.View ArticlePubMedGoogle Scholar
- Aspenstrom P: Effectors for the Rho GTPases. Curr Opin Cell Biol. 1999, 11: 95-102. 10.1016/S0955-0674(99)80011-8.View ArticlePubMedGoogle Scholar
- Ridley AJ, Paterson HF, Johnston CL, Diekmann D, Hall A: The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell. 1992, 70: 401-10. 10.1016/0092-8674(92)90164-8.View ArticlePubMedGoogle Scholar
- Goren I, Müller E, Schiefelbein D, Gutwein P, Seitz O, Pfeilschifter J, Frank S: Akt1 Controls Insulin-Driven VEGF Biosynthesis from Keratinocytes: Implications for Normal and Diabetes-Impaired Skin Repair in Mice. J Invest Dermatol. 2008,Google Scholar
- Pankow S, Bamberger C, Klippel A, Werner S: Regulation of epidermal homeostasis and repair by phosphoinositide 3-kinase. J Cell Sc. 2006, 119: 4033-46. 10.1242/jcs.03175.View ArticleGoogle Scholar
- Kumar N, Afeyan R, Kim HD, Lauffenburger DA: Multipathway model enables prediction of kinase inhibitor cross-talk effects on migration of Her2-overexpressing mammary epithelial cells. Mol Pharmacol. 2008, 73: 1668-78. 10.1124/mol.107.043794.PubMed CentralView ArticlePubMedGoogle Scholar
- Nguyen BP, Gil SG, Carter WG: Deposition of laminin 5 by keratinocytes regulates integrin adhesion and signaling. J Biol Chem. 2000, 275: 31896-907. 10.1074/jbc.M006379200.View ArticlePubMedGoogle Scholar
- Frank DE, Carter WG: Laminin 5 deposition regulates keratinocyte polarization and persistent migration. J Cell Sci. 2004, 117: 1351-63. 10.1242/jcs.01003.View ArticlePubMedGoogle Scholar
- Zhang K, Kramer RH: Laminin 5 deposition promotes keratinocyte motility. Exp Cell Res. 1996, 227: 309-22. 10.1006/excr.1996.0280.View ArticlePubMedGoogle Scholar
- Carter WG, Kaur P, Gil SG, Gahr PJ, Wayner EA: Distinct functions for integrins alph3 beta 1 in focal adhesions and alpha 6 beta 4/bullous pemphigoid antigen in a new stable anchoring contact (SAC) of keratinocytes: relation to hemidesmosomes. J Cell Biol. 1990, 111: 3141-54. 10.1083/jcb.111.6.3141.View ArticlePubMedGoogle Scholar
- Shang M, Koshikawa N, Schenk S, Quaranta V: The LG3 module of laminin-5 harbors a binding site for integrin alpha3beta1 that promotes cell adhesion, spreading, and migration. J Biol Chem. 2001, 276: 33045-53. 10.1074/jbc.M100798200.View ArticlePubMedGoogle Scholar
- Goldfinger LE, Hopkinson SB, deHart GW, Collawn S, Couchman JR, Jones JC: The alpha3 laminin subunit, alpha6beta4 and alpha3beta1 integrin coordinately regulate wound healing in cultured epithelial cells and in the skin. J Cell Sci. 1999, 112: 2615-29.PubMedGoogle Scholar
- Bitar MS, Labbad ZN: Transforming growth factor-beta and insulin-like growth factor-I in relation to diabetes-induced impairment of wound healing. J Surg Res. 1996, 61: 113-9. 10.1006/jsre.1996.0090.View ArticlePubMedGoogle Scholar
- Goren I, Müller E, Pfeilschifter J, Frank S: Severely impaired insulin signaling in chronic wounds of diabetic ob/ob mice: a potential role of tumor necrosis factor-alpha. Am J Pathol. 2006, 168: 765-77. 10.2353/ajpath.2006.050293.PubMed CentralView ArticlePubMedGoogle Scholar
- Brooks PC, Klemke RL, Schon S, Lewis JM, Schwartz MA, Cheresh DA: Insulin-like growth factor receptor cooperates with integrin alpha v beta 5 to promote tumor cell dissemination in vivo. J Clin Invest. 1997, 99: 1390-8. 10.1172/JCI119298.PubMed CentralView ArticlePubMedGoogle Scholar
- Rho O, Bol DK, You J, Beltrán L, Rupp T, DiGiovanni J: Altered expression of insulin-like growth factor I and its receptor during multistage carcinogenesis in mouse skin. Mol Carcinog. 1996, 17: 62-9. 10.1002/(SICI)1098-2744(199610)17:2<62::AID-MC2>3.0.CO;2-V.View ArticlePubMedGoogle Scholar
- Hébrant A, van Staveren WC, Delys L, Solís DW, Bogdanova T, Andry G, Roger P, Dumont JE, Libert F, Maenhaut C: Long-term EGF/serum-treated human thyrocytes mimic papillary thyroid carcinomas with regard to gene expression. Exp Cell Res. 2007, 313: 3276-84. 10.1016/j.yexcr.2007.06.019.View ArticlePubMedGoogle Scholar
- Faber-Elman A, Lavie V, Schvartz I, Shaltiel S, Schwartz M: Vitronectin overrides a negative effect of TNF-alpha on astrocyte migration. FASEB J. 1995, 9: 1605-13.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.